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1875-9572/Copyright ª 2016, TaiwanBackground: Acute bronchiolitis is one of the main respiratory emergencies in young children.
Although supportive therapy is recommended, substantial inconsistency in the clinical usage of
inhaled treatments has been reported. In the present study, we evaluated the association be-
tween different types of nebulized therapies in clinical practice and the length of stay (LOS) of
young children hospitalized with nonsevere bronchiolitis.
Methods: Medical records of 195 patients with bronchiolitis, without evidence of pneumonia or
congenital/chronic respiratory conditions, were stratified with respect to the type of inhala-
tion therapy received: nebulized albuterol (Group 1, nZ 53), nebulized albuterol with 3% sa-
line (Group 2, n Z 38), nebulized 3% saline alone (Group 3, n Z 33), or no inhaled treatment
(Group 4, nZ 71). Duration of hospital stay was reported with respect to the type of inhalation
therapy received after controlling for variability in patient age (months), oxygen saturation,
respiratory score, and use of other treatments (antibiotics, oxygen supplementation, and/or
corticosteroids). LOS is presented in terms of mean and 95% confidence interval (95% CI).
Results: The groups were similar except for differences in the mean level of oxygen saturation,
respiratory score, and corticosteroid use. Children in Group 4 had the lowest mean respiratory
score due to a lesser prevalence of wheezing and/or retractions than in other groups. The LOS
for children in Groups 1 and 4 was shorter (43.2 hours, 95% CI 34.9e51.3, and 44.1 hours, 95% CI
37.3e51.0, respectively) than in Groups 2 and 3 (72 hours, 95% CI 62.1e81.6, and 65.1 hours,
95% CI 54.7e75.6, respectively) (p < 0.02). The mean LOS in each group did not change signif-
icantly after adjustment for covariants.of Pediatrics, Jersey Shore University Medical Center, 1945 Route 33, Neptune, NJ 07753, USA.
alth.com (J.M. Pinto).
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Bronchiolitis length of stay by type of therapy 141Conclusion: Prolonged hospitalization of children younger than 2 years with acute, nonsevere
bronchiolitis is associated with administration of nebulized 3% saline, independent of age, clin-
ical presentation of disease, or inclusion of other treatments in their management.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Acute bronchiolitis is a viral respiratory infection that oc-
curs in children younger than 2 years, associated with the
development of edema, mucus plugging, and obstruction of
the lower airways.1e3 Although, in general, acute bron-
chiolitis is a self-limited condition, children with moderate-
to-severe respiratory distress, deoxygenation, and dehy-
dration require hospitalization for observation and sup-
portive therapy.4 Acute bronchiolitis has been recognized
as the main respiratory emergency leading to hospitaliza-
tion of up to 3% of young children diagnosed with the
condition.2,5 Of the total annual hospital charges in the
USA, around 2 billion dollars are attributed to hospitaliza-
tion of children with bronchiolitis.6 Pharmacological ther-
apies for bronchiolitis with corticosteroids, antibacterials,
antivirals, and/or bronchodilators are not recommended by
the American Academy of Pediatrics for the routine man-
agement of hospitalized children.4 Although the evidence
does not support routine administration of bronchodila-
tors,7 their use in the clinical management of bronchiolitis
is relatively frequent and varies widely between clinical
settings.8e10 A number of studies have examined the effect
of inhaled hypertonic saline (HS) on bronchiolitis outcomes
and show an overall reduction in the length of stay (LOS)
and good tolerability of inhaled HS treatments in children
with mild-to-moderate bronchiolitis.3 However, others have
reported no benefit11e13 or a negative impact14 of nebu-
lized 3% saline on the clinical course of bronchiolitis,
including respiratory function and/or LOS. Inconsistency in
the medical literature and variability in the usage of
inhaled therapy highlight the need for further evaluation of
bronchiolitis outcomes in relation to management in the
inpatient setting. In the present report, we evaluated the
duration of hospitalization of young children with non-
severe bronchiolitis in association with the type of nebu-
lized therapy used (albuterol, albuterol with 3% HS, 3% HS,
or no inhaled treatment with bronchodilators and/or HS) in
the inpatient setting, after accounting for variability in
patients’ age, clinical presentation of disease, and inclu-
sion of other medications in treatment.2. Methods
We conducted a retrospective review of the medical re-
cords of children hospitalized with bronchiolitis between
October 2009 and September 2012 at the Jersey Shore
University Medical Center, Neptune, NJ, USA. We identified
bronchiolitis cases from the hospital’s administrative
database, using the International Classification of Diseases,Ninth Revision codes for bronchiolitis (466.11 and 466.19).
This study is a secondary analysis of collected bronchiolitis
cases to determine the relationship between LOS of young
children hospitalized with bronchiolitis and types of nebu-
lized medications included in their treatment. Children
aged  2 years, born at term gestation, without chronic
conditions (lung disease, asthma, immunodeficiency,
congenital heart disease, or cystic fibrosis), and without
evidence of chest radiography-confirmed pneumonia15 and/
or admission to the pediatric intensive care were eligible
for inclusion in this analysis. Demographics (age and
gender), medical history (history of eczema or wheezing,
and family history of asthma), clinical data at admission
(oxygen saturation, respiratory rate, wheezing, air ex-
change, and retractions), laboratory data (white blood cell
count), and treatments administered (supplemental oxy-
gen, corticosteroids, antibiotics, inhaled bronchodilator,
and/or 3% HS) were extracted from the medical records of
selected patients using a standardized collection tool that
was approved by the Meridian Health Institutional Review
Board of Jersey Shore University Medical Center in
Neptune, NJ, USA.
Respiratory symptoms at admission (respiratory rate,
wheezing, air exchange, and retractions) listed in the
medical records were used to calculate and categorize the
respiratory scores, as < 3 versus  3.16 Hypoxia at admis-
sion was defined as oxygen saturation (SpO2) of < 90%
because oxygen supplementation is recommended for pa-
tients whose SpO2 is < 90%.
4 LOS was defined as the dif-
ference in hours between admission and discharge. The
time of discharge was identified by the attending pedia-
trician’s order in each of the bronchiolitis cases. We defined
the study population as patients with nonsevere bronchio-
litis, because patients were from the general pediatric
ward and did not require continuous positive airway pres-
sure and/or intubation during the course of disease.
2.1. Data presentation and statistical analysis
LOS for children hospitalized with bronchiolitis was
analyzed with respect to the types of solutions used for
nebulized therapy: 1.25 mg/3 mL (isotonic standard solu-
tion) albuterol every 4 hours prior to discharge (Group 1),
1.25 mg of albuterol with 4 mL of 3% HS every 4e6 hours
prior to discharge (Group 2), 4 mL of 3% HS alone every
6e8 hours prior to discharge (Group 3), and no inhaled
treatments (Group 4).
We compared demographic and clinical data of the
groups using Chi-square and analysis of variance for cate-
gorical and continuous variables, respectively. The LOS for
children included in each group is presented before and
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Figure 1 Prevalence (%) of wheezing, abnormal air ex-
change, tachypnea, and retractions in children with bron-
chiolitis at admission in the treatment groups. The prevalence
of decreased aeration in Group 4 was zero. The p values show
statistically significant differences in the prevalence of
wheezing (p < 0.02) and retractions (p < 0.002) in children
from different treatment groups. * Group 1 received nebulized
albuterol only. y Group 2 received nebulized albuterol þ 3%
saline. z Group 3 received nebulized 3% saline only. x Group 4
received no inhaled treatment.
142 J.M. Pinto et alafter controlling for potentially clinically significant factors
or those that were found to be significantly (p < 0.05)
associated with the outcome in unadjusted analyses using a
general linear model. Data were analyzed statistically using
STATISTICA 12 (StatSoft Inc., Tulsa, OK, USA) and are pre-
sented as proportion (%), mean  standard deviation, and
95% confidence interval (95% CI).
3. Results
Of the 232 patients identified via the administrative data-
base, 195 met the inclusion criteria. Among them, 53
(27.2%), 38 (19.5%), 33 (16.9%), and 71 (36.4%) received
nebulized treatments with albuterol solution alone (Group
1), albuterol solution with 3% HS (Group 2), 3% HS alone
(Group 3), or no inhaled treatment (Group 4), respectively.
Overall, inhaled nebulized treatments with 3% HS were
used in the management of 36.4% of children (Groups 2 and
3) and albuterol in 46.7% (Groups 1 and 2). Differences were
recorded between groups for the mean level of SpO2%,
respiratory score, and use of corticosteroids (Table 1).
Children in Group 4 had the lowest mean respiratory score,
and the number of children with respiratory scores 3 was
higher in Groups 1 and 2 compared to that in Groups 3 and
4. As shown in Figure 1, wheezing and/or retractions were
less likely to be recorded for patients in Group 4 as
compared to patients in Groups 1e3. The LOS for children
in Groups 1 and 4 was significantly shorter than that in
Groups 2 and 3 (Figure 2). As shown in Figure 2, the mean
LOS in each group did not change significantly after
adjustment for age, SpO2%, respiratory score, and use of
oxygen, antibiotics, or corticosteroids. No adverse event
association with inhaled therapy administration was
recorded.Table 1 Comparison of demographic and clinical variables wi
bronchiolitis.
Characteristics Group 1*
(n Z 53)
Gr
(n
Age (mo) 6.1  5.3 5.0
Age  12 mo (%) 88.7 89
Feeding (any breast milk) (%)ǁ 24.4 30
Gender: male (%) 56.6 71
History of wheezing &/or eczema (%) 13.2 10
Family history of asthma (%) 32.1 35
WBC > 15,000 mm3 (%) 17.8 (8/45) 13
SpO2 (%) 96.3  3.1 96
SpO2  90% (%) 3.8 5.3
Respiratory score 1.3  0.9 1.4
Respiratory score  3 (%) 42.1 35
Corticosteroid use (%) 11.5 7.9
Antibiotics use (%) 30.2 23
O2 supplementation (%) 26.4 36
O2 Z oxygen; SpO2 Z pulse oximetry level; WBC Z white blood cell
* Group 1 received nebulized albuterol only.
y Group 2 received nebulized albuterol þ 3% saline.
z Group 3 received nebulized 3% saline only.
x Group 4 received no inhaled treatment.
ǁ Included patients  12 months old.4. Discussion
This study evaluates the effect of differences in clinical
practice with regard to the use of inhaled therapies on the
duration of hospitalization of children with nonsevere
bronchiolitis, at a single inpatient setting. More than one-
third of patients received no inhalation therapy and an
equivalent number received HS in nebulized solution with
or without albuterol. Almost half of patients received
nebulized albuterol alone or in combination with HS. Theth respect to treatment type for children hospitalized with
oup 2y
Z 38)
Group 3z
(n Z 33)
Group 4x
(n Z 71)
p
 4.8 4.1  3.9 4.6  5.4 0.31
.5 93.9 91.5 0.09
.3 25.8 40.6 0.13
.0 63.6 46.5 0.08
.5 6.1 5.6 0.45
.1 40.6 37.1 0.97
.9 (5/36) 10.7 (3/28) 26.3 (15/57) 0.26
.6  3.3 97.1  2.8 97.9  2.2 < 0.01
6.1 1.4 0.56
 1.1 1.3  1.0 0.69  0.80 < 0.001
.1 14.3 5.4 < 0.01
0 0 < 0.01
.7 36.4 23.9 0.53
.8 27.3 22.5 0.46
count.
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Figure 2 Comparison of LOS in hours (mean and 95% CI) of
children hospitalized with bronchiolitis with respect to treat-
ment received prior to and after the adjustment to covariants*.
The p value (< 0.02) illustrates a statistically significant dif-
ference in duration of hospitalization between treatment
groups prior to and after adjustment to the covariants. * Co-
variants included child age, pulse oximetry level, respiratory
score, use of oxygen, antibiotics, and corticosteroids. y Group 1
received nebulized albuterol only. z Group 2 received nebu-
lized albuterol þ 3% saline. x Group 3 received nebulized 3%
saline only. ǁ Group 4 received no inhaled treatment.
CI Z confidence interval; LOS Z length of stay.
Bronchiolitis length of stay by type of therapy 143LOS for patients who did not receive any inhaled therapy
was comparable to that of patients who were treated with
nebulized albuterol without 3% HS, regardless of age,
respiratory symptoms, and use other treatments. The
obtained results are similar to those of reports from small
and heterogeneous placebo (inhaled normal saline)
controlled trials that show no beneficial effect of routine
use of bronchodilators on the LOS of children with bron-
chiolitis.7 Inclusion of inhaled 3% HS in the treatment of
our patients was associated with prolongation of their
hospitalization, independent of other covariants. Our
findings are contrary to those of other reports that show
w1-day mean reduction in the duration of hospitalization
for children with bronchiolitis using inhaled HS3,17 or no
effect11e13 of inhaled HS on the LOS. Nevertheless, vari-
ability in dosage regimens and cointerventions,18 as well
as no short-term improvement in clinical scores with in-
clusion of 3% HS in inhaled therapy19,20 and no additional
benefit of adding 3% HS to nebulized solution with bron-
chodilators,21 all call into question the beneficial effects
of 3% HS. A revised American Academy of Pediatrics clin-
ical practice guideline published in 2014 identified
administration of nebulized HS to infants and children
hospitalized for bronchiolitis as a weak recommendation
due to inconsistent findings.22
Although our study is observational in nature, the re-
sults were controlled for the important covariants that
may, along with the type of nebulized therapy adminis-
tered, influence the duration of hospitalization in childrenwith bronchiolitis. In addition to age and respiratory score,
we included oxygen level and oxygen supplementation in
the model because of the reported associations of the
need for oxygen supplementation23,24 and lower pulse
oximeter readings23 with a longer LOS. We also controlled
for the use of antibiotics in the regression analysis because
longer hospitalization of children with bronchiolitis who
were treated with antibiotics has been reported,25
although a recently published Cochrane review showed
no effect of use of antibacterial therapy on the LOS of
children younger than 2 years who were hospitalized with
bronchiolitis.26
We acknowledge several limitations of the present
report that may affect the conclusions. Although the
retrospective design increases the risk for bias in data
collection and the effect of confounding variables, the
following strategies were used to decrease the risk of bias
and maintain internal validity: (1) standardization of the
data collection tool; (2) precise measurement of LOS (in
hours); (3) exclusion of bronchiolitis cases with evidence of
pneumonia; and (4) control of important covariants for
their possible association with the duration of hospitaliza-
tion. Moreover, the power analysis showed that the sample
size of 195 patients used in this study is sufficient to detect
a 30% difference in the mean LOS between groups stratified
by the type of nebulized therapy administered with a power
of 87% and a < 0.05. We admit that the weakness of using
data from a single inpatient setting is uncertain generaliz-
ability of results to other practices. However, our investi-
gation is based on the analysis of an age- and disease-
specific population of patients with bronchiolitis, and
additional analysis of 99 randomly selected cases from the
195 cases included in the database showed the same asso-
ciation between the LOS and type of nebulized therapy
used for patients’ management: Group 1 (nZ 28, 40.1, 95%
CI 29.3e50.9 hours), Group 2 (n Z 18, 69.6, 95% CI
48.6e90.5 hours), Group 3 (nZ 20, 68.3, 95% CI 47.9e88.7
hours), and Group 4 (nZ 33, 41.2, 95% CI 33.7e48.8 hours;
p < 0.0001). Despite that, similar evaluation of nebulized
therapies used in the routine clinical management of
bronchiolitis may be needed to verify that the obtained
results are reproducible in different settings. The role of
demographic and clinical characteristics in addition to
treatments administered should be assessed when deter-
mining the duration of hospitalization of children with
bronchiolitis.
In conclusion, prolonged hospitalization of children
younger than 2 years with acute, nonsevere bronchiolitis is
associated with administration of nebulized 3% saline, in-
dependent of age, clinical presentation of disease, or in-
clusion of other treatments in their management.Conflicts of interest
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